Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 51-58 , January 2006

Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome

  • Ananya Choudhury, MA, MRCP (FRCR)
    • ,
  • Andrew Cuddihy, PhD
    • ,
  • Robert G. Bristow, MD, PhD (FRCPC)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert G. Bristow, MD, PhD, FRCPC, Department of Radiation Oncology, Princess Margaret Hospital, Room 5-923 610 University Avenue Toronto, Ontario, Canada.

References 

  1. Faulhaber O , Bristow RG . Basis of cell kill following clinical radiotherapy, in Sluyser, Mels (eds) (Application of Apoptosis to Cancer Treatment) . Dordrecht, The Netherlands: Springer Publishing; 2005;
  2. Bristow RG , Harrington L . Genetic instability and DNA repair . In:  Tannock IFHR ,  Harrington L ,  Bristow RG editor. The Basic Science of Oncology . 4th ed.. New York: McGraw-Hill Ltd; 2005;p. 77–99
  3. Diggle CP , Bentley J , Knowles MA , et al.   Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts . Nucleic Acids Res . 2005;33:2531–2539
  4. Wachters FM , van Putten JW , Maring JG , et al.   Selective targeting of homologous DNA recombination repair by gemcitabine . Int J Radiat Oncol Biol Phys . 2003;57:553–562
  5. Lukas J , Lukas C , Bartek J . Mammalian cell cycle checkpoints (signalling pathways and their organization in space and time) . DNA Repair (Amst) . 2004;3:997–1007
  6. Bradshaw PS , Stavropoulos DJ , Meyn MS . Human telomeric protein TRF2 associates with genomic double-strand breaks as an early response to DNA damage . Nat Genet . 2005;37:193–197
  7. Cuddihy AR , Bristow RG . The p53 protein family and radiation sensitivity (Yes or no?) . Cancer Metastasis Rev . 2004;23:237–257
  8. Wilson GD . Radiation and the cell cycle, revisited . Cancer Metastasis Rev . 2004;23:209–225
  9. Sullivan A , Syed N , Gasco M , et al.   Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo . Oncogene . 2004;23:3328–3337
  10. Eastman A . Cell cycle checkpoints and their impact on anticancer therapeutic strategies . J Cell Biochem . 2004;91:223–231
  11. Collis SJ , Swartz MJ , Nelson WG , et al.   Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors . Cancer Res . 2003;63:1550–1554
  12. Hickson I , Zhao Y , Richardson CJ , et al.   Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM . Cancer Res . 2004;64:9152–9159
  13. Swisher SG , Roth JA , Komaki R , et al.   Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy . Clin Cancer Res . 2003;9:93–101
  14. Wildner O . Clinical trials (The sensitizing side of Onyx-015) . Gene Ther . 2005;12:386–387
  15. Komarov PG , Komarova EA , Kondratov RV , et al.   A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy . Science . 1999;285:1733–1737
  16. Kawabe T . G2 checkpoint abrogators as anticancer drugs . Mol Cancer Ther . 2004;3:513–519
  17. Noble ME , Endicott JA , Johnson LN . Protein kinase inhibitors (Insights into drug design from structure) . Science . 2004;303:1800–1805
  18. Xiao HH , Makeyev Y , Butler J , et al.   7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines . Radiat Res . 2002;158:84–93
  19. Syljuasen RG , Sorensen CS , Hansen LT , et al.   Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage . Mol Cell Biol . 2005;25:3553–3562
  20. Mukhopadhyay UK , Senderowicz AM , Ferbeyre G . RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells . Cancer Res . 2005;65:2872–2881
  21. Tsuchida E , Urano M . The effect of UCN-01 (7-hydroxystaurosporine), a potent inhibitor of protein kinase C, on fractionated radiotherapy or daily chemotherapy of a murine fibrosarcoma . Int J Radiat Oncol Biol Phys . 1997;39:1153–1161
  22. Bishay K , Ory K , Olivier MF , et al.   DNA damage-related RNA expression to assess individual sensitivity to ionizing radiation . Carcinogenesis . 2001;22:1179–1183
  23. Djuzenova C , Muhl B , Schakowski R , et al.   Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radiosensitive cancer patients . Br J Cancer . 2004;90:2356–2363
  24. Fan R , Kumaravel TS , Jalali F , et al.   Defective DNA strand break repair after DNA damage in prostate cancer cells (implications for genetic instability and prostate cancer progression) . Cancer Res . 2004;64:8526–8533
  25. Taneja N , Davis M , Choy JS , et al.   Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy . J Biol Chem . 2004;279:2273–2280
  26. Wyman C , Ristic D , Kanaar R . Homologous recombination-mediated double-strand break repair . DNA Repair (Amst) . 2004;3:827–833
  27. Raderschall E , Stout K , Freier S , et al.   Elevated levels of Rad51 recombination protein in tumor cells . Cancer Res . 2002;62:219–225
  28. Farmer H , McCabe N , Lord CJ , et al.   Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy . Nature . 2005;434:917–921
  29. Collis SJ , Tighe A , Scott SD , et al.   Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells . Nucleic Acids Res . 2001;29:1534–1538
  30. Russell JS , Brady K , Burgan WE , et al.   Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity . Cancer Res . 2003;63:7377–7383
  31. Slupianek A , Schmutte C , Tombline G , et al.   BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance . Mol Cell . 2001;8:795–806
  32. Soldatenkov VA , Potaman VN . DNA-binding properties of poly(ADP-ribose) polymerase (a target for anticancer therapy) . Curr Drug Targets . 2004;5:357–365
  33. Bryant HE , Schultz N , Thomas HD , et al.   Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase . Nature . 2005;434:913–917
  34. Weterings E , van Gent DC . The mechanism of non-homologous end-joining (A synopsis of synapsis) . DNA Repair . 2004;3:1425–1435
  35. Riballo E , Kuhne M , Rief N , et al.   A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci . Mol Cell . 2004;16:715–724
  36. Peng Y , Woods RG , Beamish H , et al.   Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM . Cancer Res . 2005;65:1670–1677
  37. Durant S , Karran P . Vanillins—A novel family of DNA-PK inhibitors . Nucleic Acids Res . 2003;31:5501–5512
  38. Willmore E , de Caux S , Sunter NJ , et al.   A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia . Blood . 2004;103: 4659–4565
  39. Veuger SJ , Curtin NJ , Richardson CJ , et al.   Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1 . Cancer Res . 2003;63:6008–6115
  40. Banath JP , Macphail SH , Olive PL . Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines . Cancer Res . 2004;64:7144–7149
  41. McBride WH , Iwamoto KS , Syljuasen R , et al.   The role of the ubiquitin/proteasome system in cellular responses to radiation . Oncogene . 2003;22:5755–5773
  42. Krogan NJ , Lam MH , Fillingham J , et al.   Proteasome involvement in the repair of DNA double-strand breaks . Mol Cell . 2004;16:1027–1034
  43. Kurland JF , Meyn RE . Protease inhibitors restore radiation-induced apoptosis to Bcl-2-expressing lymphoma cells . Int J Cancer . 2001;96:327–333
  44. Teicher BA , Ara G , Herbst R , et al.   The proteasome inhibitor PS-341 in cancer therapy . Clin Cancer Res . 1999;5:2638–2645
  45. Pajonk F , Himmelsbach J , Riess K , et al.   The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells . Cancer Res . 2002;62:5230–5235
  46. Bartkova J , Horejsi Z , Koed K , et al.   DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis . Nature . 2005;434:864–870
  47. Qvarnstrom OF , Simonsson M , Johansson KA , et al.   DNA double strand break quantification in skin biopsies . Radiother Oncol . 2004;72:311–317
  48. Ma BB , Bristow RG , Kim J , et al.   Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents . J Clin Oncol . 2003;21:2760–2776

 Supported by operating grants from the Terry Fox Foundation, National Cancer Institute of Canada, Ontario Cancer Research Network, the Prostate Cancer Research Foundation of Canada, and the US Army DOD Prostate Cancer Research Program. RGB is a Canadian Cancer Society Research Scientist. The first two authors contributed equally to this manuscript.

PII: S1053-4296(05)00051-2

doi: 10.1016/j.semradonc.2005.08.007

Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 51-58 , January 2006

Article Tools

* Image Usage & Resolution